KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $3.7 billion.

  • Takeda Pharmaceutical's Other Accumulated Expenses fell 88.45% to $3.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.7 billion, marking a year-over-year decrease of 88.45%. This contributed to the annual value of $3.9 billion for FY2025, which is 882.56% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Other Accumulated Expenses stood at $3.7 billion, which was down 88.45% from $3.4 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Other Accumulated Expenses peaked at $5.1 billion during Q1 2021, and registered a low of $3.3 billion during Q3 2024.
  • Over the past 5 years, Takeda Pharmaceutical's median Other Accumulated Expenses value was $4.1 billion (recorded in 2023), while the average stood at $4.2 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Other Accumulated Expenses soared by 1177.59% in 2021, and later crashed by 1613.25% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Other Accumulated Expenses (Quarter) stood at $4.7 billion in 2021, then decreased by 4.45% to $4.5 billion in 2022, then decreased by 12.6% to $4.0 billion in 2023, then fell by 5.98% to $3.7 billion in 2024, then fell by 0.88% to $3.7 billion in 2025.
  • Its Other Accumulated Expenses stands at $3.7 billion for Q4 2025, versus $3.4 billion for Q3 2025 and $3.6 billion for Q2 2025.